Investor Presentation

6 Investor presentation First six months of 2022 Diabetes value market leadership increased by 1.5%-points to 31% Novo Nordisk global diabetes value market share Diabetes value market leadership expansion driven by the GLP-1 franchise 60% Diabetes GLP-1 -Insulin 54.8% 49.1% 50% 46.4% 51.5% Novo NordiskⓇ Diabetes care sales grew by 15% with global value market share increase driven by GLP-1 market share gains in both IO and NAO Insulin value market share has slightly increased from 44.0% to 44.1% in the last 12 months GLP-1 value market share has increased by 3.3%-points in the last 12 months, driven by: OzempicⓇ launches and uptake in 75 countries RybelsusⓇ uptake in North America Operations and launches in International Operations 44.1% 44.6% 44.0% 44.1% 40% . 31.0% 28.2% 29.1% 29.6% 30% 0% 2019 2020 2021 2022 CER: Constant exchange rates; IO: International Operations; NAO: North America Operations Source: IQVIA MAT, May 2022 (Spot rate) Note: Sales growth rates are at CER

View entire presentation